BUZZ-HK-listed TransThera climbs on new drug application

Reuters12-19

** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences (Nanjing) Inc 2617.HK climb 3% to HK$173

** Stock on course to end the week up 5.9%, snapping three straight weekly losess

** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)

** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co

** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece

** YTD, Hang Seng Biotech index .HSBIO up 74.3%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592131490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592131490","market":"nz","top_or_hot":-1,"title":"BUZZ-HK-listed TransThera climbs on new drug application","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-HK-listed TransThera climbs on new drug application </title></head><body><p>** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences (Nanjing) Inc <span>2617.HK</span> climb 3% to HK$173    </p><p>** Stock on course to end the week up 5.9%, snapping three straight weekly losess</p><p>** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)</p><p>** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co</p><p>** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece</p><p>** YTD, <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Biotech index <span>.HSBIO</span> up 74.3%</p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-HK-listed TransThera climbs on new drug application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-HK-listed TransThera climbs on new drug application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-19 10:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-HK-listed TransThera climbs on new drug application </title></head><body><p>** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences (Nanjing) Inc <span>2617.HK</span> climb 3% to HK$173    </p><p>** Stock on course to end the week up 5.9%, snapping three straight weekly losess</p><p>** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)</p><p>** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co</p><p>** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece</p><p>** YTD, <a href=\"https://laohu8.com/S/HSNGF\">Hang Seng</a> Biotech index <span>.HSBIO</span> up 74.3%</p><p> (Reporting by Donny Kwok)</p><p> ((donny.kwok@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL1N3XP02I:1","article_id":"2592131490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592131490","pubTimestamp":1766112441,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-HK-listed TransThera climbs on new drug application ** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences  Inc 2617.HK climb 3% to HK$173    ** Stock on course to end the week up 5.9%, snapping three straight weekly losess** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration ** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece** YTD, Hang Seng Biotech index .HSBIO up 74.3%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技"},"translate_title":"BUZZ-HK上市公司Tranthera因新药申请而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":0.9},"content_text":"BUZZ-HK-listed TransThera climbs on new drug application ** Shares of therapy developer for oncology, inflammatory and cardiometabolic diseases TransThera Sciences (Nanjing) Inc 2617.HK climb 3% to HK$173    ** Stock on course to end the week up 5.9%, snapping three straight weekly losess** TransThera said new drug application for its Tinengotinib tablets for treatment of metastatic cholangiocarcinoma in adults has been accepted by the Center for Drug Evaluation of China's National Medical Products Administration (NMPA)** There is no assurance that the relevant product will ultimately be successfully developed and marketed - Co** Stock, which debuted on June 23, up 1,190% so far from the offer price of HK$13.15 apiece** YTD, Hang Seng Biotech index .HSBIO up 74.3% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592131490","isCrawlerRequest":true}